1. Editor-in-Chief’s Commentary: Collaborative Models for Drug Development, Evaluation, and Clinical Use

   • Stephen P. Spielberg

   Commentary 30 December 2013 Pages: 630 - 631

2. Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases

   • Diane Stephenson
   • Enrique Aviles
   • Maria Isaac

   Therapeutic and Regulatory Innovation 30 December 2013 Pages: 632 - 638

3. The Multiple Sclerosis Outcome Assessments Consortium: Bringing the Community Together to Shape the Future of Multiple Sclerosis Drug Development

   • Janet Woodcock
   • Anne M. Rowzee

   Therapeutic and Regulatory Innovation 30 December 2013 Pages: 639 - 640

4. Rheumatoid Arthritis Disease Progression Modeling

   • Russell Reeve
   • Lei Pang
   • Wei Xiao

   Therapeutic and Regulatory Innovation 30 December 2013 Pages: 641 - 650

5. New Governance Mechanisms to Optimize Protocol Design

   • Kenneth A. Getz
   • Jennifer Kim
   • Kenneth I. Kaitin

   Therapeutic and Regulatory Innovation 30 December 2013 Pages: 651 - 655

6. An Exploratory Study on the Policies of Health Care Institutions in the New England Region of the United States Regarding Third-Party Access to Medical Records of Research Participants: Potential Effects on the Legal and Ethical Conduct of Clinical Trials

   • Mark Arquiza

   Therapeutic and Regulatory Innovation 30 December 2013 Pages: 656 - 664

7. Globalizing Medical Information: The Executive Nurse as a Primary Director

   • Timothy Fish

   International Perspectives 30 December 2013 Pages: 665 - 669

8. Statistics, Quality Review Issues, and Beyond for Generic Drug Applications in Taiwan

   • Lin-Chau Chang
   • Churn-Shiouh Gau

   International Perspectives 30 December 2013 Pages: 670 - 677

9. Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies

   • Li-Ling Liu
   • Neil McAuslane
   • Jaw-Jou Kang

   International Perspectives 30 December 2013 Pages: 678 - 683

10. Legal Requirements, Definitions, and Standards for Non-interventional Drug Studies: A Global Picture of Variability—Results and Conclusions From a Single-Institution Survey

    • Markus Hartmann
    • Patricia Schaffner

    International Perspectives 30 December 2013 Pages: 684 - 691

11. Approvals of Pharmaceutical Drugs in China in the Post—Drug Registration Regulation II Era

    • Tiantian Zhang
    • Jianhong Tao
    • Chuanbin Wu

    International Perspectives 30 December 2013 Pages: 692 - 698

12. Investigation Into the Antinfluenza Agent Oseltamivir Distributed via the Internet in Japan

    • Natsumi Takahashi
    • Hirohito Tsuboi
    • Kazuko Kimura

    International Perspectives 30 December 2013 Pages: 699 - 705

13. Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence

    • Nasir Tajure Wabe
    • Nezif Hussien Dekama
    • Desta Hiko Gemeda

    International Perspectives 30 December 2013 Pages: 706 - 714

14. Overview of the Regulation of Medical Devices and Drugs in the European Union and the United States

    • Fiona Masterson
    • Kathryn Cormican

    International Perspectives 30 December 2013 Pages: 715 - 722

15. DIA/NORD 2013 US Conference on Rare Diseases and Orphan Products: Poster Abstracts

    Abstracts 30 December 2013 Pages: 723 - 740

16. Local Evaluation and Blinded Central Review Comparison: A Victim of Meta-Analysis Shortcomings

    • David Raunig
    • Gregory Goldmacher
    • James Conklin

    Letter to the Editor Open access 30 December 2013 Pages: NP1 - NP2